Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-09-30

FDA Approved: TAGRISSO — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approved a supplemental application for TAGRISSO (osimertinib) submitted by AstraZeneca Pharmaceuticals LP. This action constitutes regulatory approval rela…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TAGRISSO (osimertinib)

Snippet

SUPPL AP for TAGRISSO (OSIMERTINIB)